NEW YORK -- Voluntary offseason workout programs are intended to provide training, teaching and physical conditioning for players. The calendar for 2026 is below. As per Article 21 of the Collective ...
Police in East Brunswick are asking for the public’s help as they try to find thieves who stole $100,000 worth of copper wire from telephone poles this week. Verizon reported the large-scale theft, ...
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated ...
DENVER — The selective tyrosine kinase 2 (TYK2) inhibitor envudeucitinib emerged superior to apremilast and placebo in two phase 3 trials of people with moderate-to-severe psoriasis. The oral TYK2 ...
Thieves broke into the Magnani-Rocca Foundation outside Parma, Italy, officials said, and made off with pieces worth millions. By Ali Watkins and Josephine de La Bruyère Thieves broke into an Italian ...
Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson & ...
ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for ...
AstraZeneca (AZN) announced on Friday that its antibody therapy, tozorakimab, reached the key goals in two Phase 3 trials for patients with chronic obstructive pulmonary disease, a respiratory disease ...
The MarketWatch News Department was not involved in the creation of this content. 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 ...
Neuroinflammation and neuroimmune dysfunction are increasingly recognized as key contributors to AD pathophysiology, particularly in early disease stages. Semaglutide, already approved for type 2 ...
Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.
An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results